Drugmaker Biogen will discontinue development and marketing for Aduhelm, a landmark Alzheimer’s disease treatment that also provoked controversy over conflicting data around its efficacy, the company said Wednesday.

The FDA granted accelerated approval to the drug, which target amyloid plaques in the brain that are thought to contribute to the disease, in 2021. That endorsement was contingent upon Biogen completing a follow-up study confirming that the treatment’s benefits outweigh the risks.

But after an internal review of its research and development efforts, the company determined that it should redirect its resources toward developing other drug candidates and advancing Leqembi, another Alzheimer’s drug it’s marketing with Eisai that won traditional FDA approval last year.